Print Page  |  Close Window

SEC Filings

8-K
TEVA PHARMACEUTICAL INDUSTRIES LTD filed this Form 8-K on 02/08/2018
Entire Document
 

   
Reconciliation of our segment profit
to consolidated income before income taxes
 
Year ended December 31,
2017 2016
Audited, U.S.$ in millions
Generic medicines profit $ 2,829 $ 3,310
Specialty medicines profit 4,333 4,661
Total segment profit 7,162 7,971
Profit of other activities 86 68
Total profit 7,248 8,039
Amounts not allocated to segments:
Amortization 1,444 993
General and administrative expenses 1,330 1,285
Other asset impairments, restructuring and other items 5,074 1,419
Goodwill impairment 17,100 900
Inventory step-up 67 383
Other R&D expenses 221 426
Costs related to regulatory actions taken in facilities 47 153
Legal settlements and loss contingencies 500 899
Venezuela deconsolidation charge 396 -
Gain on sales of business (1,083) (720)
Other unallocated amounts (364) 147
Consolidated operating income (loss) $ (17,484) $ 2,154
Financial expenses - net 895 1,330
Consolidated income (loss) before income taxes (18,379) 824
(1) Includes for 2016, $133 million in inventory related-expenses in connection with the devaluation in Venezuela.